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Abstract
A series of new ethylenediamine (en) platinum(IV) complexes of the type Pt(V)enXA, with X
cyclobutane-l,l-dicarboxylato (CBDCA), dichloro or bis(decanoato) and A acetato,
dodecanoato, tetradecanoato, hexadecanoato, octadecanoato, adamantanecarboxylato (Ad) or
3(x,12(x-diformoxy-51]-cholato (DFOA) were synthesized and characterized by elemental analysis,
infrared and NMR (H and C) spectroscopic techniques.
Previous platinum(IV) compounds were usually restricted to trans-dihydroxo or trans-dichloro
platinum(IV) complexes. Recently trans-dicarboxylato platinum(IV) complexes with mainly acetate,
trifluoracetate or shod-chain carboxylate groups (<11 carbons) in the axial position have been
described in the literature[, , ].
In this paper we report on the synthesis and characterization of a new class of ethylenediamine
platinum(IV) compounds that have high lipophilic long-chain carboxylate ligands either in the axial
or equatorial position. The platinum(IV) compounds with the lipophilic trans-carboxylate ligands in
the axial position were prepared by acylation of the trans-dihydroxo platinum(IV) species using an
acyl halide in the presence of pyridine. In contrast to previous publications[] the yields were
excellent (up to 94% !).
Introduction
cis-Diamminedichlomplatinum(ll) (cisplatin, CDDP) is widely used to treat various types of human
cancer. Although it is effective against testicular tumors, ovarian caminomas, bladder tumors and
tumors of the head and neck, its use is limited by significant severe side-effects such as
dose-dependent nephrotoxicity, ototoxicity, neurotoxicity, myelotoxicity, nausea and vomiting[]. In
an attempt to ovemome these limitations, it is desirable to develop new platinum-based anticancer
drugs with a broader spectrum of activity, reduced toxicities and an improved clinical
effectiveness. Both acceptance and quality of life of cancer patients receiving a platinum-based
chemotherapy could be further enhanced by the development of orally administrable platinum
complexes.
One strategy to attain this could be to replace the labile chlom ligands in CDDP with other leaving
groups e.g. bidentate dicarboxylates and/or to replace the non-leaving groups with bis(alkylamine),
diamine or mixed ammine/amine ligands. Several second-generation platinum drugs have entered
clinical trials over the last two decades[], such as diammine-
(cyclobutane-1,1 -dicarboxylato)platinum(I I) (carboplatin/ (1,1-diaminocyclohexane)oxalato-
platinum(ll) (oxaliplatin)In and the racemic mixture of cis-bis(neodecanoato)-trans-R,R-
[8 1,2-diaminocyclohexaneplatinum(ll) (L-NDDP) entrapped in liposomes as drug carriers, ]
Another promising strategy in the search for new platinum-based anticancer drugs could be to
convert platinum(l I) compounds into their platinum(IV) analogues. Cis-dichloro-trans-dihydroxo-
cis-bis(isopropylamine)platinum(IV) (CHIP)[] was the first platinum(IV) complex to enter clinical
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(1,2-diamino-cyclohexane)platinum(IV), was the second. Previous platinum(IV) compounds were
usually restricted to the trans-dichlom- or trans-dihydroxoplatinum(IV) species.
trans-Dicarboxylatoplatinum(IV) compounds have recently been described in the literature. This
new class of complexes is very interesting with regard to the development of platinum anticancer
drugs that can be orally administered. Clinical trials with bis(acetato)(ammine)dichlom(cyclohexyl-
amine)platinum(IV) (JM216) started a short while ago. Preclinical work has shown that JM216 has
comparable p.o. activity to i.v. administered cisplatin and carboplatin in a panel of four human
ovarian caminoma xenogmfts in vivd]. Furthermore, JM216 is well absorbed from the
gastrointestinal tract and has toxic effects comparable to those of carboplatin[].
Therefore we report here on the systematic synthesis of platinum(IV) compounds that have
trans-carboxylate ligands in the axial position. The general formula of these platinum(IV)
complexes is PtVenXA, with X cyclobutane-l,l-dicarboxylato (CBDCA), dichloro or
bis(decanoato) and A acetato, dodecanoato, tetradecanoato, hexadecanoato, octadecanoato,
adamantanecarboxylato (Ad) or 3(,12(-diformoxy-5-cholato (DFCA). The compound with the
trans-acetate ligand was prepared by the general synthetic procedure: reaction of the
trans-dihydmxoplatinum(IV) species with acetic anhydride. The yield was 93%. The new class of
ethylenediamine platinum(IV) compounds with high lipophilic carboxylate ligands in the axial
position was not prepared by the conventional synthetic pathway. In contrast to previous
publications we used an acyl halide in the presence of pyridine with very good yields.
Materials and Methods
Chemicals
Silversulfate, hydrogen peroxide and acetic anhydride were pumhased from Merck while
ethylenediamine was obtained from Roth, cyclobutane-l,l-dicarboxylic acid from EGA and
potassiumtetrachlomplatinate from Degussa. All chemicals obtained from commemial suppliers
were used as received. Water was used bidistilled while the required acyl halides were prepared
by reaction of the corresponding carboxylic acid with thionyl chloride. Workup was carried out by
general methods.
Physical Measurements
Elemental analyses were performed in our own laboratories. R spectra were recorded in KBr
pellets in the range of 400-4400 cm-
on a Bruker FS 66. NMR spectra were measured using a
Bruker Ac 200 MHz spectrometer. NMR (H, C) spectra were measured in [D]DMSO, CDCI,
[D] acetone or DO containing [D] acetone as reference. The Pt NMR spectrum was obtained
in CDCI and referenced using an external sample of HPtCI in DO at 0.0 ppm.
Preparation of Platinum Complexes
The trans-dicarboxylatoplatinum(IV) compounds with chlom ligands in the equatorial position were
synthesized as shown in Scheme 1.
IPtCl, + en = PtenCl= + 2 KCl (1]
PtenCl= + H=O= m PtenCl=(OH)= (2)
PtenCl=(OH)= + 2RCOCl PtenCI=(OCOR)= + 2HCI (3)
Scheme 1. Synthesis of platinum(IV) compounds with chloro ligands in the equatorial position and
carboxylate ligands in the axial position.
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PtenCl was prepared according to Drew’s method[] and oxidized by hydrogen peroxide
(reactions (1) and (2)). The treatment of the trans-dihydroxoplatinum(IV) species with an acyl
halide in the presence of pyridine produced the trans-dicarboxylatoplatinum(IV) complex in very
good yields (reaction (3)).
PtOenCl. An aqueous solution of KPtCI4 (6.04 g, 15.56 mmol) was treated with ethylenediamine
(882 mg, 14.68 mmol) and stirred for 6 hours at room temperature. The precipitate that formed
was filtered, washed with water and recrystallized from DMF/methanol. Anal. Calc. for
CHCINPt: C, 7.37; H, 2.47; N, 8.59. Found" C, 7.54; H, 2.50; N, 8.60. Yield, 61%.
ptV)enCl(OH). 15 ml of 30% hydrogen peroxide were added to a suspension of Pt(")enCl (875
mg, 2.68 mmol) in 15 ml of bidistilled water. After stirring for 30 minutes at morn temperature, the
mixture was heated under reflux for 10 minutes. The suspension was cooled and the product was
filtered, washed with water and dried under reduced pressure. Anal. Calc. for CH0CINOPt" C,
6.67; H, 2.80; N, 7.78. Found: C, 6.72; H, 2.78; N, 7.77. Yield, 76%.
ptV)enCI(OCO(CH)CH). After suspending pt0VenCl(OH) (515 mg, 1.43 mmol) in 25 ml of
acetone, tetradecanoyl chloride (2.1g, 8.52 mmol) and pyridine (888 mg, 11.23 mmol) were
added. After stirring overnight at room temperature, the mixture was gently refluxed for 6 hours.
The suspension was cooled down to room temperature and 70 ml of water were added to
hydrolize the excess of acyl halide. The product and the tetradecanoic acid were filtered, washed
with water and dded in vacuo. The carboxylic acid was extracted with CHCI and the final product
was dried under reduced pressure, ptVenCI(OCO(CH)CH) was obtained as a white solid.
Anal. Calc. see Table 1. Yield, 94%.
All trans-dicarboxylatoplatinum(IV) complexes with chlom ligands in the equatorial position were
prepared in a manner similar to the one described above. The elemental analyses and yields are
listed in Table 1.
The ethylenediamine platinum(IV) complexes containing carboxylate ligands both in the equatorial
and axial position were prepared as shown in Scheme 2.
K=PtCI4 + en PtenCl= + 2KCl (1)
PtenCl= + Ag=SO, Pten(SO4)(H=O) + 2AgCl (5)
Pten(SO4)(H=O) + 2NaX = Pten)(= + Na,O4 (6)
PtenX= + H=O= = PtenX=(OH)= (7)
PtenX=(OH)= + CHsCOOCOCHs = PtenX=(OCOCHs)= (Sa)
PtenX=(OH)= + 2RCOCl PtonX=(OCOR)= + 2 HCl (Sb)
Scheme 2. Synthesis of platinum(IV) compounds with mixed carboxylate ligands.
PtenCl was prepared as described above and activated by reaction with an equimolar amount of
silversulfate (reaction (1) and (5)). The platinum(ll) complexes with different leaving groups were
produced by mixing Pten(SO4)(H20) with the in situ prepared sodium salts of the corresponding
carboxylic acids (reaction (6)). The obtained platinum(ll) carboxylates were oxidized by hydrogen
peroxide (reaction (7)). The trans-bis(acetato)platinum(IV) compound was prepared by reaction of
the trans-dihydroxoplatinum(IV) species with acetic anhydride (reaction (Sa)), whereas the
platinum(IV) complexes with the lipophilic carboxylate ligands in the axial position were
synthesized by reaction of PtenX2(OH) with an acyl halide in the presence of pyridine (reaction
(8b)).
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Table 1. Elemental Analyses of Ethylenediamine Platinum(IV) Complexes
Pt(enCl=(OCO(CH=)0CH)=
Pt(’v)encl(OcO(cH)cH)
Pt(v)encl,(OcO(cH,),,cH),
Pt(’v)enci=(OcO(cH),cH),
Pt(V)enCl(Ad)
Pt(’v)enCI(DFCA)
Pt(’ven(CBDCA)(OCO(CH)CH)
Pt(’en(CBDCA)(OCO(CH),,CH)
Pt(’V)en(CBDCA)(OCO(CH),eCH)
Pt(’Ven(OCO(CH=)CH)(OCOCH)
calc.
found
calc.
found
%C %H %CI %N %Pt
43.09 7.51 9.78 3.87 26.92
43.19 7.62 9.74 3.98 26.65
46.15 8.00 9.08 3.59 24.98
46.35 8.01 9.29 3.59 24.89
calc. 48.79 8.43 8.47 3.35 23.31
found 49.03 8.54 8.55 3.42 23.34
calc. 51.11 8.80 7.94 3.14 21.78
found 51.31 8.93 8.21 3.26 21.78
calc. 42.11 5.60 10.36 4.09 28.50
found 42.01 5.63 10.31 4.06 28.57
calc. 53.11 7.10 5.81 2.29 15.97
found 53.31 7.18 5.79 2.36 15.08
calc. 50.75 8.04 3.29 22.90
found 50.87 7.95 3.50 22.65
calc. 52.90 8.44 3.18 21.48
found 53.09 8.30 3.16 21.36
Yield (%)
89
94
92
91
88
72
68
92
calc. 54.81 8.78 2.91 20.23 89
found 54.45 8.70 3.06 20.02
calc. 43.63 7.32 3.91 27.25 93
found 43.45 7.23 3.98 27.64
Pfen(SO)(HO). An aqueous solution of silversulfate (726 mg, 2.33 mmol) was added to
Pt(")enCl (800 mg, 2.45 mmol) in 100 ml of bidistilled water. After stirring for 15 hours in the dark
at room temperature, silverchloride was removed by filtration. The yellow solution was evaporated
to dryness and the residue was dried over phosphorus(V)oxide in vacuo. Anal. Calc. for
C=H0NOsPtS: C, 6.51; H, 2.73; N, 7.59. Found" C, 6.64; H, 2.78; N, 7.70. Yield, 97%.
Pt(")en(CBDCA). Cyclobutane-1,1-dicarboxylic acid (144 mg, 2.26 mmol) was dissolved in 4.65 ml
of 1N NaOH and stirred for 30 minutes at 50C. After the addition of 835 mg (2.26 mmol)
Pt(")en(SO4)(HO) in 35 ml of water, the mixture was stirred for two hours at 50C and for 18 hours
in the dark at room temperature. The produced platinum(ll) complex was filtered, washed with
acetone and dried in vacuo. Anal. Calc. for CH4NO4Pt: C, 24.19; H, 3.55; N, 7.05. Found: C,
24.15; H, 3.56; N, 7.04. Yield, 80%.
Pt(V)en(CBDCA)(OH)z The addition of 10 ml of 30% hydrogen peroxide to a suspension of 305 mg
(768 mol) Pt(")en(CBDCA) in 15 ml of water produced a clear solution. After a few minutes, the
white product began to precipitate. The Suspension was stirred overnight at room temperature,
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filtered and washed with water. Anal. Calc. for CHNOPt: C, 22.28; H, 3.74; N, 6.50; Pt, 45.23.
Found: C, 22.37; H, 3.74; N, 6.50; Pt, 45.04. Yield, 58%.
PtV)en(CBDCA)(OCO(CH)eCH)z The following trans-dicarboxylatoplatinum(IV) compounds with
the cyclobutane-l,l-dicarboxylate ligand in the equatorial position were prepared in a manner
similar to the one used in the case of ptVenCI(OCO(CH)CH). The elemental analyses and
yields of these complexes are listed in Table 1.
Pt(’)en(OCO(CHCH)z Sodiumdecanoate, prepared in situ by mixing 3.54 ml of 1 N NaOH and
595 mg (3.45 mmol) of decanoic acid, was added to a solution of 638 mg (1.73 mmol)
Pt(")en(SO)(HO) in 10 ml of bidistilled water. After stirring for 30 minutes at 60C, one hour at
45C and two days in the dark at room temperature, the whole mixture was extracted with CHCI.
The organic layer was dried over magnesiumsulfate and evaporated to dryness. The residue was
extracted with acetone and the remaining solid was dried in vacuo. Anal. Calc. for CHNOPt:
C, 44.21; H, 7.76; N, 4.69; Pt, 32.64. Found: C, 44.37; H, 7.83; N, 4.72; Pt, 32.78. C=O, 181.94.
Pt,-1736. Yield, 76%.
Pt(V)en(OCO(CHCH)(OH)z 218 mg (365 mol) Pt(")en(OCO(CH)CHa) were suspended in 6
ml of water and 12 ml of 30% hydrogen peroxide were added. The mixture was stirred for 30
minutes at room temperature and for 5 minutes at 50C. After filtration the unreacted
ethylenediamine platinum(ll) species was extracted with CHCI. The dried product was obtained as
a white solid. Anal. Calc. for CH,NO6Pt: C, 41.83; H, 7.66; N, 4.43; Pt, 30.88. Found: C, 42.08;
H, 7.75; N, 4.41; Pt, 30.62. Yield, 23%.
PtV)en(OCO(CH)CH)(OCOCH)z Acetic anhydride (50 mg, 490 Imol) was added to a
suspension of pt0Ven(OCO(CH)CH) (40 mg, 63 imol) in 20 ml of acetone. After stirring
overnight at room temperature, the mixture was heated for 2 hours at 50C and cooled down to
room temperature. 30 ml of water were added. After an overnight storage in the refrigerator, the
white precipitate was filtered off and dried over phosphorus(V)oxide. Anal Calc. for CHNOPt:
C, 43.63; H, 7.32; N, 3.91; Pt, 27.25. Found: C, 43.45; H, 7.23; N, 3.98; Pt, 27.64. Yield, 93%.
Results and Discussion
We have synthesized a new class of ethylenediamine platinum(IV) complexes containing lipophilic
long-chain carboxylate ligands. The structural features of these complexes of the type ptVenXA
with X two chlom, two carboxylato or one bidentate dicarboxylato ligands and A carboxylato
are illustrated in Figure 1.
The compounds were characterized by elemental analysis, IR and, if soluble enough, by NMR
spectroscopy. The results of the elemental analyses are listed in Table 1. The theoretical values
are in good agreement with the actual findings.
Figure 1. Structures of the synthesized ethylenediamine platinum(IV) complexes.
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The IR spectroscopic data for the tmns-dicarboxylatoplatinum(IV) compounds is listed in Table 2.
In general, Pt0enCl and ethylenediamine platinum(ll) compounds show two single sharp and
resolvable N-H stretching absorptions. The platinum(IV) analogues with mixed dicarboxylate
ligands showed one broad band whereas platinum(IV) complexes with chlom ligands in the
equatorial and carboxylato ligands in the axial position displayed one single sharp peak in the
region of 3204 cm-
Table 2. Infrared Data for Ethylenediamine Platinum(IV) Complexes.
Pt(’venCl(OCO(CH=)oCH)
Pt(’v)encl=(OcO(cH=),=cH)=
Pt(’v)encl(OcO(CH),cH)
Pt(’vencl(OcO(cH)ecH)
Pt<’V)enCl(Ad)
Pt’V)enCI(DFCA)
Pt(’en(CBDCA)(OCO(CH),=CH)
Pt(’V)en(CBDCA)(OCO(CH),CH)
Pt(’en(CBDCA)(OCO(CH)eCH)
Pt(’V)en(OCO(CH=)CH),(OCOCH)
v(N-H)
3204
3204
3203
3204
3204
3206
3179
3181
3180
3233
IR (cm")
v.(COO)
1645
1644
1644
1645
1635
1722, 1651
1639
1647
1637
1636
v,(COO)
1374
1375
1372
1374
1329
1367
1345
1348
1346
1362
For all tmns-dicarboxylatoplatinum(IV) complexes one carbonyl vibration frequency in the region
around 1636-1651 cm was observed. In addition, PtVenCI(DFCA) showed a very strong
carbonyl absorption at 1722 cm, which is assigned to the formoxy-gmups of the
3(,12(x-diformoxy-51- chelate ligands. These values are in good agreement with those reported in
the literature[,, ].
Almost all of the synthesized platinum(IV) compounds were insoluble or barely soluble in most of
(Iv) ’the common organic solvents. Only one ill NMR spectrum of Pt enCI:(DFOA): and an 1H and
C NMR spectrum of Pt(V)enCl(Ad) and pt0V)en(OCO(CH)CH)(OCOCH) could be obtained.
TheC resonance of the carbonyl group of Pt(V)enCl(Ad) was observed at 186.5. Unfortunately,
the C=O resonance of Pt(V)en(OCO(CH)CH)=(OCOCH) was too weak to be reported.
In conclusion, a series of new ethylenediamine platinum(IV) compounds containing lipophilic
long-chain carboxylate ligands either in the axial or equatorial position have been synthesized and
characterized. Moreover, the use of the unconventional synthetic pathway via an acyl halide
produced yields up to 94%. The potentially useful trans-dicarboxylatoplatinum(IV) complexes will
be tested with regard to their antitumor activity and oral administration possibilities.
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